Physician profile
Sarah E Riley
NPI 1790338762
$4,441.32
in general payments reported to CMS, 2019-2025
22 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $12.27 · 2023: $917 · 2024: $1,773 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.91 |
| Education | $206.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $676.40 | 2023-2024 | Vtama |
| Genzyme Corporation | $664.12 | 2023-2025 | |
| Abbvie INC. | $652.22 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $390.34 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $303.46 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $251.52 | 2023-2025 | |
| Lilly USA, LLC | $169.86 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $164.93 | 2023-2024 | Sotyktu |
| Atricure, INC. | $141.18 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Leo Pharma INC. | $130.84 | 2023-2025 | Adbry |
| Amgen INC. | $128.30 | 2024-2025 | Otezla |
| Ucb, INC. | $125.01 | 2021-2025 | Bimzelx |
| Incyte Corporation | $115.52 | 2023-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $106.21 | 2024-2025 | |
| Almirall LLC | $103.84 | 2024-2025 | Seysara |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $91.04 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $52.90 | 2025 | Zoryve |
| Pfizer INC. | $49.74 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.14 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $33.90 | 2024 | Aklief |
| Verrica Pharmaceuticals INC. | $21.92 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.93 | 2025 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.